Evaluation of the effects of combination therapy with branched-chain amino acid and zinc supplements on nitrogen metabolism in liver cirrhosis

Hepatology Research

Volumn 37, Issue 8, 2007, Pages 615-619

  Hayashi, Miho ^a   Ikezawa, Kenji ^a   Ono, Akiko ^a   Okabayashi, Sachiyo ^a   Hayashi, Yoshito ^a   Shimizu, Satoshi ^a   Mizuno, Tatsuyoshi ^a   Maeda, Kosaku ^a   Akasaka, Tomofumi ^a   Naito, Masafumi ^a   Michida, Tomoki ^a   Ueshima, Dan ^b   Nada, Takayuki ^b   Kawaguchi, Kiyotaka ^b   Nakamura, Tekefumi ^b   Katayama, Kazuhiro ^a  

^a OSAKA KOSEI NENKIN HOSPITAL   (Japan)

^b Kitano Hospital   (Japan)

Author keywords

Albumin; Ammonia; Branched chain amino acid; Fischer ratio; Urea cycle

Indexed keywords

ALBUMIN; AMMONIA; BILIRUBIN; BRANCHED CHAIN AMINO ACID; ISOLEUCINE; LEUCINE; LIVACT GRANULES; NITROGEN; UNCLASSIFIED DRUG; VALINE; ZINC; ZINC SULFATE;

ADULT; AGED; ALBUMIN BLOOD LEVEL; AMMONIA BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; LIVER CIRRHOSIS; MALE; MONOTHERAPY; NITROGEN METABOLISM; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; ZINC BLOOD LEVEL;

EID: 34347347125     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2007.00095.x     Document Type: Article

References (17)

1. Christensen E, Schlichting P, Fauerholdt L et al. Prognostic value of Child-Turcotte criteria in medically treated cirrhosis. Hepatology 1984; 4: 430-5.
2. Alberino F, Gatta A, Amodio P et al. Nutrition and survival in patients with liver cirrhosis. Nutrition 2001; 17: 445-50.
3. Tajika M, Kato M, Mohri H et al. Prognostic value of energy metabolism in patients with liver cirrhosis. Nutrition 2002; 18: 229-34.
4. Moriwaki H, Miwa Y, Tajika M et al. Branched-chain amino acids as a protein- and energy-source in liver cirrhosis. Biochem Biophys Res Comm 2004; 313: 405-9.
5. Fischer JE, Baldessarini RI. False neurotransmitter and hepatic failure. Lancet 1971; 2: 75-80.
6. Horst D, Grace ND, Conn HO et al. Comparison of dietary protein with an oral branched chain-enriched amino acid treatment in chronic hepatic encephalopathy: A randomized controlled trial. Hepatology 1984; 4: 279-87.
7. Marchesini G, Bianchi G, Merli M et al. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: A double blind, randomized trial. Gastroenterology 2003; 124: 1792-801.
8. Muto Y, Sato S, Watanabe A et al. Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol 2005; 3: 705-13.
9. Hayashi M, Ohnishi H, Kawade Y, Muto Y, Takahashi Y. Augmented utilization of branched-chain amino acids by skeletal muscle in decompensated liver cirrhosis in special relation to ammonia detoxication. Gastroenterol Jpn 1981; 16: 64-70.
10. Bode JC, Hanisch P, Henning H, Koenig W, Richter FW, Bode C. Hepatic zinc content in patients with various stages of alcoholic liver disease and in patients with chronic active and chronic persistent hepatitis. Hepatology 1988; 8: 1605-9.
11. Reding P, Duchateau J, Bataille C. Oral zinc supplementation improves hepatic encephalopathy. Results of a randomized controlled trial. Lancet 1984; ii: 493-5.
12. Katayama K. Ammonia and hepatic encephalopathy. Hepatol Res 2004; 30S: S71-8.
13. Riggio O, Merli M, Capocaccia L et al. Zinc supplementation reduces blood ammonia and increases liver ornithine transcarbamylase activity in experimental cirrhosis. Hepatology 1992; 16: 785-9.
14. Marchesini G, Fabbri A, Bianchi G, Brizi M, Zoli M. Zinc supplementation and amino acid-nitrogen metabolism in patients with advanced cirrhosis. Hepatology 1996; 23: 1084-92.
15. Lockwood AH, McDonald JM, Reiman RE et al. The dynamics of ammonia metabolism in man. Effects of liver disease and hyperammoninemia. J Clin Invest 1979; 63: 449-60.
16. Hara K, Yonezawa K, Weng QR et al. Amino acid sufficiency and mTOR regulate p70S6 kinase and eIF-4E BP1 through a common effector mechanism. J Biol Chem 1998; 273: 14484-94.
17. Katayama K, Ooka Y, Kikkawa S et al. The relationship between amino acid-nitrogen metabolism and plasma zinc in patients with chronic liver disease. Kanzou 2001; 42: 120-5.